Non-Vitamin K antagonist oral anticoagulants for the prevention of recurrent venous thromboembolism

Thrombosis Research

Volumn 144, Issue , 2016, Pages 12-20

  Bauersachs, Rupert ^a,b  

^a KLINIKUM DARMSTADT   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Deep vein thrombosis; Non Vitamin K antagonist oral anticoagulant; Pulmonary embolism; Risk factor; Treatment; Venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; DABIGATRAN; PLACEBO; RIVAROXABAN; SULODEXIDE; WARFARIN; VITAMIN K GROUP;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; DRUG EFFICACY; HUMAN; INTERNATIONAL NORMALIZED RATIO; PRIORITY JOURNAL; RECURRENT DISEASE; RISK ASSESSMENT; TREATMENT DURATION; VENOUS THROMBOEMBOLISM; ANTAGONISTS AND INHIBITORS; CHEMOPROPHYLAXIS; PROCEDURES; SECONDARY PREVENTION;

ANTICOAGULANTS; CHEMOPREVENTION; HUMANS; RECURRENCE; SECONDARY PREVENTION; VENOUS THROMBOEMBOLISM; VITAMIN K;

EID: 84973520113     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2016.05.022     Document Type: Review

References (92)

1. C.E. Mahan, M.E. Borrego, A.L. Woersching, R. Federici, R. Downey, J. Tiongson, and et al. Venous thromboembolism: annualised United States models for total, hospital-acquired and preventable costs utilising long-term attack rates Thromb. Haemost. 108 2012 291 302
2. S. Barco, A.L. Woersching, A.C. Spyropoulos, F. Piovella, and C.E. Mahan European Union-28: an annualised cost-of-illness model for venous thromboembolism Thromb. Haemost. 115 2016 800 808
3. A.T. Cohen, G. Agnelli, F.A. Anderson, J.I. Arcelus, D. Bergqvist, J.G. Brecht, and et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality Thromb. Haemost. 98 2007 756 764
4. E. Oger Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale Thromb. Haemost. 83 2000 657 660
5. F.A. Anderson Jr., H.B. Wheeler, R.J. Goldberg, D.W. Hosmer, N.A. Patwardhan, B. Jovanovic, and et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study Arch. Intern. Med. 151 1991 933 938
6. M.D. Silverstein, J.A. Heit, D.N. Mohr, T.M. Petterson, W.M. O'Fallon, and L.J. Melton III Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study Arch. Intern. Med. 158 1998 585 593
7. G.E. Raskob, P. Angchaisuksiri, A.N. Blanco, H. Buller, A. Gallus, B.J. Hunt, and et al. Thrombosis: a major contributor to global disease burden Arterioscler. Thromb. Vasc. Biol. 34 2014 2363 2371
8. J.A. Heit, D.N. Mohr, M.D. Silverstein, T.M. Petterson, W.M. O'Fallon, and L.J. Melton III Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study Arch. Intern. Med. 160 2000 761 768
9. P. Prandoni, A.W.A. Lensing, A. Cogo, S. Cuppini, S. Villalta, M. Carta, and et al. The long-term clinical course of acute deep venous thrombosis Ann. Intern. Med. 125 1996 1 7
10. P.O. Hansson, J. Sorbo, and H. Eriksson Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors Arch. Intern. Med. 160 2000 769 774
11. R.H. White The epidemiology of venous thromboembolism Circulation 107 2003 14 18
12. N.J. Galioto, D.L. Danley, and R.J. Van Maanen Recurrent venous thromboembolism Am. Fam. Physician 83 2011 293 300
13. J.P. Galanaud, M.A. Sevestre, C. Genty, S.R. Kahn, G. Pernod, C. Rolland, and et al. Incidence and predictors of venous thromboembolism recurrence after a first isolated distal deep vein thrombosis J. Thromb. Haemost. 12 2014 436 443
14. C. Kearon, E.A. Akl, J. Ornelas, A. Blaivas, D. Jimenez, H. Bounameaux, and et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report Chest 149 2016 315 352
15. M.H. Prins, A.W.A. Lensing, R. Bauersachs, B. van Bellen, H. Bounameaux, T.A. Brighton, and et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies Thromb. J. 11 2013 21
16. G. Agnelli, H.R. Buller, A. Cohen, M. Curto, A.S. Gallus, M. Johnson, and et al. Oral apixaban for the treatment of acute venous thromboembolism N. Engl. J. Med. 369 2013 799 808
17. S. Schulman, A.K. Kakkar, S.Z. Goldhaber, S. Schellong, H. Eriksson, P. Mismetti, and et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis Circulation 129 2014 764 772
18. The Hokusai-VTE Investigators Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism N. Engl. J. Med. 369 2013 1406 1415
19. R. Hull, T. Delmore, E. Genton, J. Hirsh, M. Gent, D. Sackett, and et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis N. Engl. J. Med. 301 1979 855 858
20. C.S. Landefeld, and L. Goldman Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy Am. J. Med. 87 1989 144 152
21. W. Ageno, A.S. Gallus, A. Wittkowsky, M. Crowther, E.M. Hylek, and G. Palareti Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines Chest 141 2012 e44S e88S
22. E. Nutescu, I. Chuatrisorn, and E. Hellenbart Drug and dietary interactions of warfarin and novel oral anticoagulants: an update J. Thromb. Thrombolysis 31 2011 326 343
23. The EINSTEIN Investigators Oral rivaroxaban for symptomatic venous thromboembolism N. Engl. J. Med. 363 2010 2499 2510
24. The EINSTEIN-PE Investigators Oral rivaroxaban for the treatment of symptomatic pulmonary embolism N. Engl. J. Med. 366 2012 1287 1297
25. S. Schulman, C. Kearon, A.K. Kakkar, P. Mismetti, S. Schellong, H. Eriksson, and et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism N. Engl. J. Med. 361 2009 2342 2352
26. S. Schulman, C. Kearon, A.K. Kakkar, S. Schellong, H. Eriksson, D. Baanstra, and et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism N. Engl. J. Med. 368 2013 709 718
27. N. van Es, M. Coppens, S. Schulman, S. Middeldorp, and H.R. Buller Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials Blood 124 2014 1968 1975
28. G. Agnelli, H.R. Buller, A. Cohen, M. Curto, A.S. Gallus, M. Johnson, and et al. Apixaban for extended treatment of venous thromboembolism N. Engl. J. Med. 368 2013 699 708
29. S.V. Konstantinides, A. Torbicki, G. Agnelli, N. Danchin, D. Fitzmaurice, N. Galiè, and et al. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism Eur. Heart J. 35 2014 3033 3069
30. T. Baglin, K. Bauer, J. Douketis, H. Buller, A. Srivastava, and G. Johnson Duration of anticoagulant therapy after a first episode of an unprovoked pulmonary embolus or deep vein thrombosis: guidance from the SSC of the ISTH J. Thromb. Haemost. 10 2012 698 702
31. National Institute for Health and Care Excellence Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing. Clinical guidelines, CG144 http://guidance.nice.org.uk/CG144 2012 (accessed 4.2.16)
32. D. Farge, P. Debourdeau, M. Beckers, C. Baglin, R.M. Bauersachs, B. Brenner, and et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer J. Thromb. Haemost. 11 2013 56 70
33. National Institute for Health and Care Excellence Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism http://www.nice.org.uk/guidance/TA261 2015 (accessed 4.2.16)
34. G. Palareti Recurrent venous thromboembolism: what is the risk and how to prevent it Scientifica (Cairo) 2012 2012 391734
35. L.A. Castellucci, C. Cameron, G. Le Gal, M.A. Rodger, D. Coyle, P.S. Wells, and et al. Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis BMJ 347 2013 f5133
36. P.M. Ridker, S.Z. Goldhaber, E. Danielson, Y. Rosenberg, C.S. Eby, S.R. Deitcher, and et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism N. Engl. J. Med. 348 2003 1425 1434
37. C. Kearon, J.S. Ginsberg, M.J. Kovacs, D.R. Anderson, P. Wells, J.A. Julian, and et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism N. Engl. J. Med. 349 2003 631 639
38. S. Schulman, S. Granqvist, M. Holmström, A. Carlsson, P. Lindmarker, P. Nicol, and et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group N. Engl. J. Med. 336 1997 393 398
39. C. Kearon, M. Gent, J. Hirsh, J. Weitz, M.J. Kovacs, D.R. Anderson, and et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism N. Engl. J. Med. 340 1999 901 907
40. D. Ost, J. Tepper, H. Mihara, O. Lander, R. Heinzer, and A. Fein Duration of anticoagulation following venous thromboembolism: a meta-analysis JAMA 294 2005 706 715
41. B. Furie Do pharmacogenetics have a role in the dosing of vitamin K antagonists? N. Engl. J. Med. 369 2013 2345 2346
42. P. Prandoni, A.W.A. Lensing, A. Piccioli, E. Bernardi, P. Simioni, B. Girolami, and et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis Blood 100 2002 3484 3488
43. E.A. Akl, L. Kahale, I. Neumann, M. Barba, F. Sperati, I. Terrenato, and et al. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer Cochrane Database Syst. Rev. 6 2014 CD006649
44. E.A. Akl, L. Kahale, M. Barba, I. Neumann, N. Labedi, I. Terrenato, and et al. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer Cochrane Database Syst. Rev. 7 2014 CD006650
45. A.Y. Lee, M.N. Levine, R.I. Baker, C. Bowden, A.K. Kakkar, M. Prins, and et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer N. Engl. J. Med. 349 2003 146 153
46. A.Y. Lee, P.W. Kamphuisen, G. Meyer, R. Bauersachs, M.S. Janas, M.F. Jarner, and et al. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial JAMA 314 2015 677 686
47. A.Y. Lee Anti-thrombotic therapy in cancer patients Expert. Opin. Pharmacother. 4 2003 2213 2220
48. F. Posch, O. Konigsbrugge, C. Zielinski, I. Pabinger, and C. Ay Treatment of venous thromboembolism in patients with cancer: a network meta-analysis comparing efficacy and safety of anticoagulants Thromb. Res. 136 2015 582 589
49. C. Becattini, G. Agnelli, A. Schenone, S. Eichinger, E. Bucherini, M. Silingardi, and et al. Aspirin for preventing the recurrence of venous thromboembolism N. Engl. J. Med. 366 2012 1959 1967
50. T.A. Brighton, J.W. Eikelboom, K. Mann, R. Mister, A. Gallus, P. Ockelford, and et al. Low-dose aspirin for preventing recurrent venous thromboembolism N. Engl. J. Med. 367 2012 1979 1987
51. J. Simes, C. Becattini, G. Agnelli, J.W. Eikelboom, A.C. Kirby, R. Mister, and et al. Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration Circulation 130 2014 1062 1071
52. G.M. Andreozzi, A.A. Bignamini, G. Davi, G. Palareti, J. Matuska, M. Holy, and et al. Sulodexide for the prevention of recurrent venous thromboembolism: the Sulodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis (SURVET) study: a multicenter, randomized, double-blind, placebo-controlled trial Circulation 132 2015 1891 1897
53. V. Agarwal, O.J. Phung, V. Tongbram, A. Bhardwaj, and C.I. Coleman Statin use and the prevention of venous thromboembolism: a meta-analysis Int. J. Clin. Pract. 64 2010 1375 1383
54. A. Squizzato, M. Galli, E. Romualdi, F. Dentali, P.W. Kamphuisen, L. Guasti, and et al. Statins, fibrates, and venous thromboembolism: a meta-analysis Eur. Heart J. 31 2010 1248 1256
55. M. Pai, N.S. Evans, S.J. Shah, D. Green, D. Cook, and M.A. Crowther Statins in the prevention of venous thromboembolism: a meta-analysis of observational studies Thromb. Res. 128 2011 422 430
56. K. Rahimi, N. Bhala, P. Kamphuisen, J. Emberson, S. Biere-Rafi, V. Krane, and et al. Effect of statins on venous thromboembolic events: a meta-analysis of published and unpublished evidence from randomised controlled trials PLoS Med. 9 2012 e1001310
57. C.D. Nguyen, C. Andersson, T.B. Jensen, A. Gjesing, A.M. Schjerning Olsen, H.C. Malta, and et al. Statin treatment and risk of recurrent venous thromboembolism: a nationwide cohort study BMJ Open 3 2013 e003135
58. S. Biere-Rafi, B.A. Hutten, A. Squizzato, W. Ageno, P.C. Souverein, A. de Boer, and et al. Statin treatment and the risk of recurrent pulmonary embolism Eur. Heart J. 34 2013 1800 1806
59. M. Schmidt, S.C. Cannegieter, S.A. Johannesdottir, O.M. Dekkers, E. Horváth-Puhó, and H.T. Sørensen Statin use and venous thromboembolism recurrence: a combined nationwide cohort and nested case-control study J. Thromb. Haemost. 12 2014 1207 1215
60. P.S. Wells, M. Gebel, M.H. Prins, B.L. Davidson, and A.W.A. Lensing Influence of statin use on the incidence of recurrent venous thromboembolism and major bleeding in patients receiving rivaroxaban or standard anticoagulant therapy Thromb. J. 12 26 2014
61. P.A. Kyrle, F.R. Rosendaal, and S. Eichinger Risk assessment for recurrent venous thrombosis Lancet 376 2010 2032 2039
62. M.P. Donadini, W. Ageno, E. Antonucci, B. Cosmi, M.J. Kovacs, G. Le Gal, and et al. Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis: a patient-level meta-analysis Thromb. Haemost. 111 2014 172 179
63. G. Palareti How I treat isolated distal deep vein thrombosis (IDDVT) Blood 123 2014 1802 1809
64. C. Kearon, F.A. Spencer, D. O'Keeffe, S. Parpia, S. Schulman, T. Baglin, and et al. D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study Ann. Intern. Med. 162 2015 27 34
65. J. Donzé, N. Rodondi, G. Waeber, P. Monney, J. Cornuz, and D. Aujesky Scores to predict major bleeding risk during oral anticoagulation therapy: a prospective validation study Am. J. Med. 125 2012 1095 1102
66. J.A. Nieto, R. Solano, N. Trapero Iglesias, N. Ruiz-Giménez, C. Fernández-Capitán, B. Valero, and et al. Validation of a score for predicting fatal bleeding in patients receiving anticoagulation for venous thromboembolism Thromb. Res. 132 2013 175 179
67. K. Dahri, and P. Loewen The risk of bleeding with warfarin: a systematic review and performance analysis of clinical prediction rules Thromb. Haemost. 98 2007 980 987
68. J. Hippisley-Cox, and C. Coupland Predicting risk of upper gastrointestinal bleed and intracranial bleed with anticoagulants: cohort study to derive and validate the QBleed scores BMJ 349 2014 g4606
69. Anon. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study Circulation 112 2005 416 422
70. C. Huerta, S. Johansson, M.A. Wallander, and L.A. García Rodríguez Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom Arch. Intern. Med. 167 2007 935 943
71. C.E. Chee, A.A. Ashrani, R.S. Marks, T.M. Petterson, K.R. Bailey, L.J. Melton III, and et al. Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study Blood 123 2014 3972 3978
72. H. Bounameaux, and A. Perrier Duration of anticoagulation therapy for venous thromboembolism Hematology Am. Soc. Hematol. Educ. Program 252-258 2008 2008
73. J.W. Eikelboom, and J.I. Weitz A replacement for warfarin. The search continues Circulation 116 2007 131 133
74. F. Boutitie, L. Pinede, S. Schulman, G. Agnelli, G. Raskob, J. Julian, and et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials BMJ 342 2011 d3036
75. S. Schulman Advances in the management of venous thromboembolism Best Pract. Res. Clin. Haematol. 25 2012 361 377
76. A. Tosetto, A. Iorio, M. Marcucci, T. Baglin, M. Cushman, S. Eichinger, and et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH) J. Thromb. Haemost. 10 2012 1019 1025
77. M.A. Rodger, S.R. Kahn, P.S. Wells, D.A. Anderson, I. Chagnon, G. Le Gal, and et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy CMAJ 179 2008 417 426
78. M. Marcucci, A. Iorio, J.D. Douketis, S. Eichinger, A. Tosetto, T. Baglin, and et al. Risk of recurrence after a first unprovoked venous thromboembolism: external validation of the Vienna Prediction Model with pooled individual patient data J. Thromb. Haemost. 13 2015 775 781
79. Bayer Pharma AG Xarelto® summary of product characteristics http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/000944/WC500057108.pdf 2015 (accessed 21.3.16)
80. Boehringer Ingelheim International GmbH Pradaxa® summary of product characteristics http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/000829/WC500041059.pdf 2016 (accessed 21.3.16)
81. Bristol-Myers Squibb, Pfizer Eliquis® summary of product characteristics http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/002148/WC500107728.pdf 2016 (accessed 21.3.16)
82. Daiichi Sankyo Europe GmbH Lixiana® summary of product characteristics http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/002629/WC500189045.pdf 2015 (accessed 21.3.16)
83. Janssen Pharmaceuticals Inc Xarelto® prescribing information http://www.xareltohcp.com/sites/default/files/pdf/xarelto-0.pdf 2015 (accessed 4.2.16)
84. Daiichi Sankyo Inc Savaysa® prescribing information http://dsi.com/prescribing-information-portlet/getPIContent?productName=Savaysa&inline=true 2015 (accessed 4.2.16)
85. Boehringer Ingelheim Pharmaceuticals Inc Pradaxa® prescribing information http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf 2015 (accessed 1.3.16)
86. Bristol-Myers Squibb Company, Pfizer Inc Eliquis® prescribing information http://packageinserts.bms.com/pi/pi-eliquis.pdf 2015 (accessed 4.2.16)
87. L. Bamber, M.Y. Wang, M.H. Prins, C. Ciniglio, R. Bauersachs, A.W.A. Lensing, and et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis Thromb. Haemost. 110 2013 732 741
88. M.H. Prins, L. Bamber, S.J. Cano, M.Y. Wang, P.M. Erkens, R. Bauersachs, and et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial Thromb. Res. 135 2015 281 288
89. T.E. Warkentin Aspirin for dual prevention of venous and arterial thrombosis N. Engl. J. Med. 367 2012 2039 2041
90. J.I. Weitz, R. Bauersachs, J. Beyer-Westendorf, H. Bounameaux, T.A. Brighton, A.T. Cohen, and et al. Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Rationale for and design of the EINSTEIN CHOICE study Thromb. Haemost. 114 2015 645 650
91. M.C. Vedovati, F. Germini, G. Agnelli, and C. Becattini Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis Chest 147 2015 475 483
92. M. Carrier, C. Cameron, A. Delluc, L. Castellucci, A.A. Khorana, and A.Y. Lee Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis Thromb. Res. 134 2014 1214 1219